Replies to post #229272 on Anavex Life Sciences Corp (AVXL)

[mike_dotcom]

Poor girl will probably be dead before it gets approved - if it ever does.

[XenaLives]

I believe 2-73 will help as this is also a demyelinating disease.

In the mean time I'd look into NAC. Google "nac and demyelinatoin"

Protective Effects of N-Acetyl-L-Cysteine in Human ... - NCBI
https://www.ncbi.nlm.nih.gov › pmc › articles › PMC4396975
by D Park - ?2015 - ?Cited by 14 - ?Related articles
Mar 31, 2015 - It was also confirmed that NAC attenuated demyelination in the corpus callosum, a white matter region vulnerable to HIE. Conclusion.
Physiological Effects of N-Acetyl Cysteine in Patients With ...
https://clinicaltrials.gov › show › NCT03032601
Jan 26, 2017 - The overall goal of this study will be to determine whether NAC will help to support cerebral ... NAC, is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. .... Demyelinating Autoimmune Diseases, CNS
Glutathione in multiple sclerosis - SAGE Journals
https://journals.sagepub.com › doi › pdf
by AN Carvalho - ?2014 - ?Cited by 60 - ?Related articles
cortical demyelination, leading to brain atrophy.1. Importantly, reactive oxygen species ..... (NAC) was found to have promising protective effects for several ...

[falconer66a]

CMT (Charcot–Marie–Tooth disease ), much in the manner of multiple sclerosis, is caused by deterioration of the myelin sheath, the protein insulation around neurons. With an adequate myelin sheath, nerve impulses travel normally along nerves. With deterioration or weakening of the myelin sheath, nerve impulses are lost or disrupted. Hence, the severe muscular and other symptoms.

Might blarcamesine (Anavex 2-73) be therapeutic? Such has been the question for multiple sclerosis. Clinical trials in humans will have to decide the question; probably sometime in the future.

The viability of blarcamesine against multiple sclerosis has, for some time, been a matter of interest. As I recall, previously MS was listed as a target disease on the Anavex website. But not in recent periods. But (am I not correct on this?) MS appeared in the new blarcamesine patent just issued to Anavex Life Sciences Corp? If the drug can maintain or restore the degraded myelin of nerves with multiple sclerosis, good chance, at least to some degree, it could do that for individuals with Charcot–Marie–Tooth disease.